Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Citius Pharmaceuticals stock
Learn how to easily invest in Citius Pharmaceuticals stock.
Citius Pharmaceuticals Inc is a biotechnology business based in the US. Citius Pharmaceuticals shares (CTXR) are listed on the NASDAQ and all prices are listed in US Dollars. Citius Pharmaceuticals employs 15 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Citius Pharmaceuticals
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CTXR – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Citius Pharmaceuticals stock price (NASDAQ: CTXR)Use our graph to track the performance of CTXR stocks over time.
Citius Pharmaceuticals shares at a glance
|Latest market close||$0.98|
|52-week range||$0.83 - $3.85|
|50-day moving average||$1.03|
|200-day moving average||$1.56|
|Wall St. target price||$6.67|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.20|
Buy Citius Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Citius Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Citius Pharmaceuticals price performance over time
|1 week (2022-06-17)||10.88%|
|1 month (2022-05-23)||N/A|
|3 months (2022-03-24)||-48.31%|
|6 months (2021-12-23)||N/A|
|1 year (2021-06-25)||-74.42%|
|2 years (2020-06-26)||-29.20%|
|3 years (2019-06-27)||4.92%|
|5 years (2017-06-26)||6.22|
Citius Pharmaceuticals financials
|Gross profit TTM||$0|
|Return on assets TTM||-13.35%|
|Return on equity TTM||-22.6%|
|Market capitalisation||$142.7 million|
TTM: trailing 12 months
Citius Pharmaceuticals share dividends
We're not expecting Citius Pharmaceuticals to pay a dividend over the next 12 months.
Have Citius Pharmaceuticals's shares ever split?
Citius Pharmaceuticals's shares were split on a 1:15 basis on 8 June 2017. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Citius Pharmaceuticals shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Citius Pharmaceuticals shares which in turn could have impacted Citius Pharmaceuticals's share price.
Citius Pharmaceuticals share price volatility
Over the last 12 months, Citius Pharmaceuticals's shares have ranged in value from as little as $0.831 up to $3.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Citius Pharmaceuticals's is 1.6484. This would suggest that Citius Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Citius Pharmaceuticals overview
Citius Pharmaceuticals, Inc. , a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. .
Frequently asked questionsWhat percentage of Citius Pharmaceuticals is owned by insiders or institutions?
Currently 8.423% of Citius Pharmaceuticals shares are held by insiders and 18.434% by institutions. How many people work for Citius Pharmaceuticals?
Latest data suggests 15 work at Citius Pharmaceuticals. When does the fiscal year end for Citius Pharmaceuticals?
Citius Pharmaceuticals's fiscal year ends in September. Where is Citius Pharmaceuticals based?
Citius Pharmaceuticals's address is: 11 Commerce Drive, Cranford, NJ, United States, 07016 What is Citius Pharmaceuticals's ISIN number?
Citius Pharmaceuticals's international securities identification number is: US17322U2078 What is Citius Pharmaceuticals's CUSIP number?
Citius Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 17322U207
More guides on Finder
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
How to buy NYIAX (NYX) stock when it goes public
Everything we know about the NYIAX IPO, plus information on how to buy in.
How to buy Adamas One Corp (JEWL) stock when it goes public
Everything we know about the Adamas One Corp IPO, plus information on how to buy in.
How to buy Glucose Health (GLUC) stock when it goes public
Everything we know about the Glucose Health IPO, plus information on how to buy in.
How to buy Boustead Wavefront (BOUW) stock when it goes public
Everything we know about the Boustead Wavefront IPO, plus information on how to buy in.
How to buy ParaZero Technologies (PRZO) stock when it goes public
Everything we know about the ParaZero Technologies IPO, plus information on how to buy in.
Ask an Expert